SCHEMBL1780033

SCHEMBL1780033

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2ccco2)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.44
ALDH1A1 P00352 11/20 0.44
HPGD P15428 6/20 0.44
MAPK1 P28482 5/20 0.44
HSD17B10 Q99714 4/20 0.44
ATM Q13315 2/20 0.44
TSHR P16473 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
HTT P42858 2/20 0.43
MAPT P10636 5/20 0.42
NPSR1 Q6W5P4 4/20 0.42
POLB P06746 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ESR1 P03372 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
TP53 P04637 2/20 0.41
GAA P10253 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742604 0.93 KDM4E (0.46) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1779425 0.91 MAPK1 (0.46) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1778509 0.88 RXFP1 (0.41) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1781437 0.87 BTK (0.45) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1778410 0.86 ALDH1A1 (0.40) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1780244 0.86 HSD17B10 (0.38) KDM4EALDH1A1HSD17B10TSHRHTT
SCHEMBL1778268 0.85 ALDH1A1 (0.39) KDM4EALDH1A1HSD17B10ATMTSHR
SCHEMBL4592688 0.85 KDM4E (0.44) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL1781046 0.85 ALDH1A1 (0.38) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL1780565 0.84 ALDH1A1 (0.40) KDM4EALDH1A1HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KDM4E 2856/4885ALDH1A1 3557/4885HPGD 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.